Shareholders Approve Amended Equity Incentive Plan with Significant Share Authorization

summarizeSummary

Zura Bio shareholders approved an amended equity incentive plan, authorizing the issuance of up to 9.6 million shares initially, with an evergreen provision for annual increases of up to 5% of outstanding shares.

check_boxKey Events · Financing and Capital Events · ZURA

• Equity Incentive Plan Approved

  Shareholders approved the Amended and Restated 2023 Equity Incentive Plan, making it effective. The Board had previously approved this plan on April 23, 2026, subject to shareholder vote.

• Significant Share Authorization

  The plan initially authorizes the issuance of up to 9,594,213 shares for equity awards, which represents a substantial portion of the company's current outstanding shares.

• Annual Evergreen Provision

  The plan includes an evergreen clause allowing for annual increases of up to the lesser of 5.0% of outstanding shares (or shares plus pre-funded warrants from 2027) or 8,059,796 shares.

• Potential Dilution

  The initial authorization alone represents over 10% of the company's estimated outstanding shares, indicating significant potential dilution for existing shareholders.

auto_awesomeAnalysis · ZURA · Life Sciences

Shareholders of Zura Bio Ltd approved an amended equity incentive plan, which initially authorizes the issuance of up to 9.6 million new shares. This plan also includes an evergreen provision for annual increases of up to 5% of outstanding shares. While essential for attracting and retaining talent, this represents a substantial potential dilution for existing shareholders, with the initial authorization alone representing over 10% of the company's estimated outstanding shares.